Avalon GloboCare (ALBT)
Markets KetoAir breath monitors and develops Catch-Up AI video software.
Something off on this page? Send us feedback.
Markets KetoAir breath acetone monitors in North America and develops Catch-Up, a beta platform that automates short-form video production for creators and marketers. Commercial progress depends on adoption of both early-stage offerings, while legacy cellular-therapy patents remain under prosecution.
Combines consumer health technology with AI content software. KetoAir is a reusable breath acetone monitor for nutritional ketosis, marketed in North America through online and social channels. Catch-Up is a beta platform being developed by Avalon Quantum AI for podcasters, creators, and marketers.
KetoAir pairs non-invasive breath testing with a mobile nutrition app. Catch-Up is designed to automate topic sourcing, clip selection, scripting, and avatar-led production, with Caylent and Amazon Web Services supporting its next development phase. Legacy cellular-therapy research has ceased, although related patents remain under prosecution.
Commercial performance depends on adoption of both early-stage offerings, third-party distribution and development relationships, evolving FDA, privacy, content, and intellectual-property rules, and continued financing. The former Freehold real-estate operation has been sold, and laboratory services have ended.
Company facts
Categories
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $39.2K · Total debt $146.1K · Total assets $14.7M · Shareholders' equity $10.1M
- Revenue
- $0
- Operating income
- −$2.1M
- Net income
- −$2.2M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | ≥ 2.27% | 453.6K shares | |
| Strategic holders1 holder · as of Aug 14, 2026 | 8.02% | 1.60M shares | |
| Otherremainder | ≤ 89.71% | 17.89M shares |
19.95M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (19.95M in the company's Sep 3, 2026 report, 4.23M elsewhere); stakes use the report.
Institutional filings for CHGA (100% of the company) are not on file here, so the institutional figure is a floor.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCStrategic | 8.02% | 1.60M | 13Gfiled Aug 14, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.31% | 61,949 | 13Fas of Mar 31, 2026 |
Equitable Holdings, Inc.Institution | 0.30% | 60,000 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 0.29% | 57,325 | 13Fas of Mar 31, 2026 |
Citadel Advisors LLCInstitution | 0.28% | 56,184 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
Not reported.